Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DW5524 in healthy volunteers
NCT07349589Phase 1Not yet recruiting
- Sponsor
- Daewon Pharm
- Start
- Feb 2026
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of DW-5524 (4 arms), sponsored by Daewon Pharm. Primary endpoints: Area Under the Curve from Time Zero to Last Measurable Concentration at 8 hours and Maximum Plasma Concentration at 8 hours. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
DW-5524
Beyond the preview
Go deeper on NCT07349589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07349589.